Compare · TNDM vs WST
TNDM vs WST
Side-by-side comparison of Tandem Diabetes Care Inc. (TNDM) and West Pharmaceutical Services Inc. (WST): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both TNDM and WST operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- WST is the larger of the two at $26.37B, about 23.7x TNDM ($1.11B).
- Both names hit the wire about 4 times in the past 4 weeks.
- TNDM has more recent analyst coverage (25 ratings vs 20 for WST).
- Company
- Tandem Diabetes Care Inc.
- West Pharmaceutical Services Inc.
- Price
- -
- -
- Market cap
- $1.11B
- $26.37B
- 1M return
- -
- +4.70%
- 1Y return
- -
- +43.81%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2013
- News (4w)
- 4
- 4
- Recent ratings
- 25
- 20
Tandem Diabetes Care Inc.
Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set. It also provides t:slim X2 insulin with Basal-IQ and control IQ technology; t:slim X2 with G5 Integration; and Tandem Device Updater, a tool that allows users to update their pump's software. In addition, the company offers t:connect, a web-based data management application, which provides a visual way to display diabetes therapy management data from the pump, continuous glucose monitoring, and supported blood glucose meters for users, their caregivers, and their healthcare providers; and Sugarmate, a mobile app for people with diabetes who use insulin. Its products in development include t:sport insulin delivery system; and connected (mobile) health offerings. Tandem Diabetes Care, Inc. has a development and commercialization agreement with Dexcom, Inc. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.
West Pharmaceutical Services Inc.
West Pharmaceutical Services, Inc. designs and produces containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging components. It also provides drug containment solutions, including Crystal Zenith, a cyclic olefin polymer in the form of vials, syringes, and cartridges; and self-injection devices, as well as a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. It serves pharmaceutical, diagnostic, and medical device companies. The company distributes its products through its sales force and distribution network, as well as contract sales agents and regional distributors. West Pharmaceutical Services, Inc. was incorporated in 1923 and is headquartered in Exton, Pennsylvania.
Latest TNDM
- Barclays initiated coverage on Tandem Diabetes Care with a new price target
- Tandem Diabetes Care to Announce Third Quarter 2026 Financial Results on November 5, 2026
- Citigroup reiterated coverage on Tandem Diabetes Care with a new price target
- Tandem Mobi Automated Insulin Delivery System Now Available in Twelve International Markets
- William Blair initiated coverage on Tandem Diabetes Care
- EVP & CHIEF FINANCIAL OFFICER Vosseller Leigh converted options into 4,120 shares and covered exercise/tax liability with 1,479 shares, increasing direct ownership by 5% to 52,040 units (SEC Form 4) to satisfy withholding tax
- PRESIDENT & CEO Sheridan John F converted options into 15,916 shares and covered exercise/tax liability with 8,099 shares, increasing direct ownership by 5% to 160,260 units (SEC Form 4) (for withholding tax)
- EVP, Chief Strategy Officer Gasser Elizabeth Anne converted options into 3,014 shares and covered exercise/tax liability with 1,618 shares (SEC Form 4) to satisfy withholding tax
- EVP & Chief Admin. Officer Morrison Susan converted options into 2,827 shares and covered exercise/tax liability with 809 shares, increasing direct ownership by 4% to 52,788 units (SEC Form 4) (tax withholding)
- EVP & Chief Operating Officer Kyrillos Jean-Claude converted options into 1,010 shares and covered exercise/tax liability with 535 shares, increasing direct ownership by 2% to 30,290 units (SEC Form 4) (for withholding tax)
Latest WST
- West to Host Third-Quarter 2026 Conference Call
- West to Highlight Industry Leadership in Packaging and Containment at CPHI Worldwide
- SEC Form 4 filed by Director Haugen Janet Brutschea
- West Pharm upgraded by Morgan Stanley with a new price target
- Sr. VP & Chief HR Officer Favorite Annette F exercised 7,524 shares at a strike of $89.64 and sold $2,671,260 worth of shares (7,524 units at $355.03) (SEC Form 4)
- Sr. VP & Chief HR Officer Favorite Annette F exercised 8,135 shares at a strike of $85.37 and sold $2,772,489 worth of shares (8,135 units at $340.81) (SEC Form 4)
- SEC Form 4 filed by President and CEO Lagarde Michel
- New insider Lagarde Michel claimed ownership of 7,850 shares (SEC Form 3)
- UBS resumed coverage on West Pharm with a new price target
- West to Participate in Upcoming Investor Conferences